G01N2405/04

Rapid Evaporative Ionisation Mass Spectrometry ("REIMS") and Desorption Electrospray Ionisation Mass Spectrometry ("DESI-MS") Analysis of Swabs and Biopsy Samples

A method is disclosed comprising providing a biological sample on a swab, directing a spray of charged droplets onto a surface of the swab in order to generate a plurality of analyte ions, and analysing the analyte ions.

Rapid evaporative ionisation mass spectrometry (“REIMS”) and desorption electrospray ionisation mass spectrometry (“DESI-MS”) analysis of swabs and biopsy samples

A method is disclosed comprising providing a biological sample on a swab, directing a spray of charged droplets onto a surface of the swab in order to generate a plurality of analyte ions, and analysing the analyte ions.

Means and Methods for Diagnosing Heart Failure in a Subject

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Cell population analysis

A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target in vitro or ex vivo cell population; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said target cell population or one or more cells and/or compounds present in said target cell population.

METHODS AND KITS FOR DETECTING AND DIAGNOSING NEUROTRAUMA
20170254822 · 2017-09-07 ·

Methods and kits for detecting and diagnosing neurotrauma (e.g., traumatic brain injury, stroke, or spinal cord injury) are provided. These methods rely on the determination of lysophosphatidic acid (LPA) and/or LPA metabolite levels in patient samples following suspected injury.

Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comorbid Diseases
20210405075 · 2021-12-30 · ·

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient.

METHOD FOR PROVIDING DIAGNOSTIC INFORMATION FOR BILIARY TRACT CANCER AND APPARATUS FOR DIAGNOSING BILIARY TRACT CANCER

The present disclosure relates to a method for providing diagnostic information for biliary tract cancer and an apparatus for diagnosing biliary tract cancer. According to an aspect of the present disclosure, there is provided a method for providing diagnostic information for biliary tract cancer including obtaining biological samples; measuring concentration of a marker for predicting biliary tract cancer in the biological samples; and providing diagnostic information for biliary tract cancer using the measured concentration of the marker, where the marker includes Nudifloramide.

METHODS FOR TREATING AND MONITORING PROGRANULIN-ASSOCIATED DISORDERS

The present disclosure provides methods and materials for screening a compound or monitoring a subjects response to a compound or dosing regimen for treating a PGRN-associated disorder. Methods and materials for identifying and treating a subject having a PGRN-associated disorder are also provided.

Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue

A method of ion imaging is disclosed that includes automatically sampling a plurality of different locations on a sample using a front device which is arranged and adapted to generate aerosol, smoke or vapour from the sample. Mass spectral data and/or ion mobility data corresponding to each location is obtained and the obtained mass spectral data and/or ion mobility data is used to construct, train or improved a sample classification model.

Rapid evaporative ionisation mass spectrometry (“REIMS”) and desorption electrospray ionisation mass spectrometry (“DESI-MS”) analysis of swabs and biopsy samples

A method is disclosed comprising providing a biological sample on a swab, directing a spray of charged droplets onto a surface of the swab in order to generate a plurality of analyte ions, and analysing the analyte ions.